News - Roche, Bristol-Myers Squibb


Current filters:

RocheBristol-Myers Squibb

Popular Filters

Added indications recommended by EMA/CHMP

Added indications recommended by EMA/CHMP


Along with backing for approval for six news drugs issued at the late June meeting of the European Medicines…

AvastinBayerBristol-Myers SquibbCardio-vascularEliquisEuropeEyleaKalydecoOncologyOphthalmicsPfizerPharmaceuticalRare diseasesRegulationRocheVertex Pharmaceuticals

Arrival of new hepatitis C therapies will increase the drug-treated population in China

Arrival of new hepatitis C therapies will increase the drug-treated population in China


China’s market for hepatitis C virus (HCV) drugs will be driven by an increase in its drug-treated…

Anti-viralsasunaprevirBristol-Myers SquibbChinadanoprevirGilead SciencesJanssenMarkets & MarketingOlysioPharmaceuticalRocheSovaldi

Immunotherapies show promise for non-small cell lung cancer market

Immunotherapies show promise for non-small cell lung cancer market


Immunotherapies have huge potential for the treatment of non-small cell lung cancer (NSCLC), with three…

BiotechnologyBristol-Myers SquibbMarkets & MarketingMerck & ConivolumabOncologypembrolizumabResearchRoche

Product launches to fuel lupus market growth


The systemic lupus erythematosus (SLE) treatment market in the seven major countries (7MM) will increase…

Anti-Arthritics/RheumaticsBenlystaBristol-Myers SquibbEli LillyepratuzumabGlaxoSmithKlineGlobalImmuPharmaLupuzorMerck SeronoOrenciaPharmaceuticalRituxanRochetabalumabUCB

Five big pharma firms named as high performers in annual biopharmaceutical report

Five big pharma firms named as high performers in annual biopharmaceutical report


Entry in emerging markets and expedient product launches are still driving the pharma market, according…

AmgenAstellas PharmaBristol-Myers SquibbFinancialMarkets & MarketingNovo NordiskPharmaceuticalResearchRoche

Modest growth seen for MAbs market for colorectal cancer, as late-stage pipeline is weak


The market value for monoclonal antibodies in colorectal cancer treatment will experience a moderate…

AvastinBiotechnologyBristol-Myers SquibbErbituxMarkets & MarketingMerck KGaAOncologyResearchRocheTakeda PharmaceuticalsVectibix

US patient share leaders in first-line BRAF-mutation positive malignant melanoma


According to US oncologists surveyed in the third quarter of 2013 by BioTrends Research, a unit of Decision…

Bristol-Myers SquibbGlaxoSmithKlineMarkets & MarketingMekinistNorth AmericaOncologyPharmaceuticalRocheTafinlarYervoyZelboraf

Highlights from European Cancer Congress on Kadcyla, Yervoy, Erbitux and Somatuline


A host of new oncology data was presented at the European Cancer Congress in Amsterdam, the Netherlands,…

Bristol-Myers SquibbErbituxEuropeIpsenKadcylaMerck KGaAOncologyPharmaceuticalResearchRocheSomatulineYervoy

EU5 rheumatologits rate Rituxan and Benlysta for Lupus


Rheumatologists in the top European nations ( EU5) countries (France, Germany, Italy, Spain, UK) give…

Anti-Arthritics/RheumaticsBenlystaBiogen IdecBristol-Myers SquibbEuropeGlaxoSmithKlineMarkets & MarketingOrenciaPharmaceuticalRituxanRoche

Oncologists positive on Tafinlar, Mekinist and nivolumab for unresectable malignant melanoma


US and European oncologists surveyed by health care advisory firm Decision Resources indicate that overall…

BiotechnologyBristol-Myers SquibbEuropeGlaxoSmithKlineMarkets & MarketingMekinistnivolumabNorth AmericaOncologyPharmaceuticalRocheTafinlarZelboraf

New EULAR recommendations address use of synthetic and biological DMARDs


The European League Against Rheumatism (EULAR) has this week released updated recommendations for the…

ActemraBiotechnologyBristol-Myers SquibbEuropeHealthcareMabTheraOrenciaPfizerPharmaceuticalRegulationRocheXeljanz

Oncologists favor Avastin as first-line therapy for metastatic colorectal cancer


For the treatment of metastatic colorectal cancer (mCRC), a majority of surveyed US oncologists surveyed…

AvastinBayerBiotechnologyBristol-Myers SquibbErbituxMarkets & MarketingMerck SeronoNorth AmericaOncologyPharmaceuticalRegeneronRocheSanofiStivargaZaltrap

Negative NICE guidance for Roche's Avastin and B-MS/AstraZeneca's Forxiga


UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has published draft…

AstraZenecaAvastinBristol-Myers SquibbDiabetesEuropeForxigaOncologyPharmaceuticalPricingRegulationRoche

Indian govt plans compulsory licences for trastuzumab, ixabepilone and dasatinib


The Indian government's move to issue compulsory licences to three more patented cancer drugs has left…

Asia-PacificAvastinBristol-Myers SquibbGenericsIxempraOncologyPatentsPharmaceuticalRocheSprycel

UK's NICE plans to back NHS use of two breakthrough skin cancer treatments


The UK's drugs watchdog the National Institute for Health and Clinical Excellence (NICE) this morning…

Bristol-Myers SquibbEuropeOncologyPharmaceuticalPricingRegulationRocheYervoyZelboraf

Yervoy and Zelboraf accounted for two-thirds of malignant melanoma drug market in 2011; report


The launches of Bristol-Myers Squibb's (NYSE: BMY) immunotherapy Yervoy (ipilimumab) and Roche (ROG:…

Bristol-Myers SquibbdabrafenibGlaxoSmithKlineGlobalMarkets & MarketingOncologyPharmaceuticalRochetrametinibYervoyZelboraf

Yervoy and Zelboraf rapidly penetrating metastatic patient population in USA and Europe


In the USA and Europe there is strong physician desire for new therapies for the treatment of early stage…

Bristol-Myers SquibbEuropeMarkets & MarketingNorth AmericaOncologyPharmaceuticalRocheYervoyZelboraf

Amylin said to be attracting several Big Pharma suitors


US biotech firm Amylin Pharmaceuticals (Nasdaq: AMLN), which earlier this year rebuffed a $22 per share…

AmylinAstraZenecaBiotechnologyBristol-Myers SquibbMerck & CoMergers & AcquisitionsPfizerPharmaceuticalRocheSanofiTakeda Pharmaceuticals

Roche ups bid for Illumina; M&A speculation on Amylin, Actavis


There was a plethora of merger and acquisition news coming out yesterday and this morning, first of which…

ActavisAmylinBiotechnologyBristol-Myers SquibbGenericsIlluminaMergers & AcquisitionsMylan LaboratoriesPharmaceuticalRocheWatson Pharmaceuticals

UK NICE nixes three colorectal cancer drugs; gives nod to blood thinner Eliquis


In a batch of mixed news coming from the UK’s National Institute for Health and Clinical Excellence…

AmgenAvastinBristol-Myers SquibbCardio-vascularEliquisErbituxMerck & CoMerck SeronoOphthalmicsPfizerPharmaceuticalPricingRegulationRocheVectibix

Back to top